Fig. 7

TET2 activated/upregulated TXNIP/NLRP3 in female mice. A Bodyweight in female mice at four weeks after STZ injection. n = 10, ***p < 0.001, unpaired t-test. B Fasting blood glucose in female mice at 4 weeks after STZ injection. n = 10, ***p < 0.001, unpaired t-test. C Glucose tolerance was measured in STZ-treated and control female mice at four weeks after STZ injection. n = 7, ***p < 0.001, two-way ANOVA with Bonferroni post hoc test. D Thermal hyposensitivity in the paws of the STZ-treated mice. n = 10, ***p < 0.001, unpaired t-test. E Mechanical allodynia in the paws of STZ-treated mice. n = 10, ***p < 0.001, unpaired t-test. F–I Genomic DNA 5fC and 5caC were examined in control and female STZ-diabetic mice. *p < 0.05, n = 3–4, unpaired t-test. J-S Representative Western blot bands and quantifications of the protein expression of TET2, TXNIP, NLRP3, pro-caspase-1, and cleaved-caspase-1 in female DRG tissue at 4 weeks of STZ injection, *p < 0.05, **p < 0.01, n.s., not significant; unpaired t-test. n = 3–4. Experiments were repeated at least 3 times independently